Last updated on September 2018

Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed

Brief description of study

The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of switching to tenofovir alafenamide (TAF) versus continuing tenofovir disoproxil fumarate (TDF) in virologically suppressed adults with chronic hepatitis B virus (HBV) infection.

Clinical Study Identifier: NCT02979613

Contact Investigators or Research Sites near you

Start Over

Gilead Study Team

Majadahonda, Spain